Evidence map›Paper›PMID 39650164›Full record

ReviewFrontiers in pharmacology2024

Expert consensus on the off-label use in China of drugs for rare hematologic diseases (2024 edition).

Boxin Zhao, Xuan Zhou, Ping Zheng, Bo Zhang, Xiaoqin Feng, Jie Chen, Lisheng Cai, Yilu Chen, Liya He, Jianfen Su and 18 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Boxin Zhao *Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xuan Zhou *Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Ping ZhengDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Bo ZhangDepartment of Pharmacy, Peking Union Medical College Hospital, Beijing, China.
Xiaoqin FengDepartment of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jie ChenDepartment of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Lisheng CaiDepartment of Hematology, Shenzhen Second People's Hospital, Shenzhen, China.
Yilu ChenDepartment of Pharmacy, Guangzhou Women and Children's Medical Center, Guangzhou, China.
Liya HeDepartment of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou, China.
Jianfen SuDepartment of Pharmacy, Panyu Central Hospital, Guangzhou, China.
Shuqin ChengDepartment of Hematology, Panyu Central Hospital, Guangzhou, China.
Yingtong ZengDepartment of Pharmacy, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, China.
Guowei LiDepartment of Hematology, Huizhou Central People's Hospital, Huizhou, China.
Bo JiDepartment of Clinical Pharmacy, General Hospital of Southern Theatre Command of PLA, Guangzhou, China.
Jianlong WuDepartment of Pharmacy, Shenzhen Second People's Hospital, Shenzhen, China.
Weiyi FengDepartment of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Maobai LiuDepartment of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.
Yiran JinDepartment of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Taotao LiuPharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Xiaolan MoDepartment of Pharmacy, Guangzhou Women and Children's Medical Center, Guangzhou, China.
Junyan WuDepartment of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Hui WuDepartment of Pharmacy, First Affiliated Hospital of Kunming Medical University, Kunming, China.
Hongliang ZhangPharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Zhichang ZhengDepartment of Pharmacy, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Zhihua ZhengGuangdong Pharmaceutical Association, Guangzhou, China.
Jing SunDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yilei LiDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Guangdong Pharmaceutical Association, Hematology Group of Rare Disease Expert Committee of Guangdong Pharmaceutical Association

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug package inserts are a crucial foundation for clinical medication practices and serve as the legal basis for guiding rational drug use and ensuring patient safety and efficacy. As rare disease treatments evolve, current package inserts often need to meet the clinical requirements for treating such conditions, frequently resulting in off-label drug use. This consensus is derived from discussions between Guangdong Pharmaceutical Association Hematologic Rare Diseases Group experts. The consensus aims to provide a framework and reference for the clinical application of off-label drug use in treating rare hematologic diseases.

Indexed as

evidence based pharmacyexpert consensushematological diseaseoff-label drug userare diseases

Identifiers

PMID39650164
PMCPMC11621627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.